Understanding differences in outcomes for patients with Lewy body disorders
Project III: Heterogeneity of Outcomes in Synucleinopathies: Insights from Genomics and Proteomics
This study is looking into why people with Lewy body disorders, which affect thinking and memory, have different experiences with cognitive decline, and it aims to find out how genetics and certain proteins play a role, so we can better tailor treatments for those affected.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10935311 on NIH RePORTER |
What this research studies
This research investigates why patients with Lewy body disorders, which involve the misfolding of a protein called alpha-synuclein, experience varying cognitive outcomes. By examining genetic risk factors and protein biomarkers, the study aims to identify characteristics that influence when cognitive decline occurs in these patients. The research will utilize advanced genomic and proteomic techniques to uncover the underlying mechanisms of cognitive impairment in Lewy body disorders. This could lead to more personalized approaches to treatment and management for affected individuals.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Lewy body disorders, including those with varying degrees of cognitive impairment.
Not a fit: Patients with Lewy body disorders who do not have any cognitive impairment may not benefit directly from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved understanding and management of cognitive decline in patients with Lewy body disorders.
How similar studies have performed: Previous research has shown promise in understanding genetic and biomarker influences on cognitive outcomes in neurodegenerative diseases, suggesting potential for success in this approach.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Chen-Plotkin, Alice S — University of Pennsylvania
- Study coordinator: Chen-Plotkin, Alice S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.